Running title: Tiam1, rac1 and RhoA provides a target for drug therapy.
Introduction
Pancreatic cancer is the fourth most common cause of cancer-related death worldwide and is always associated with a poor prognosis (1) . Poor clinical outcomes may be due to most patients being diagnosed with advanced disease with extensive metastasis, high resistance of tumors to chemotherapy, and lack of effective chemotherapeutic agents (2). Investigation of the underlying mechanisms driving pancreatic cancer progression may reveal molecular Tiam1 (T lymphoma invasion and metastasis 1) is a rac1-specific guanine nucleotide exchange factor and is believed to act as an oncogene in many cancers (3) (4) (5) (6) . Tiam1 maintains the specificity of rac1 towards specific downstream effector pathways, while rac1 regulates cell survival and cell cycle progression (7, 8) . Together, Tiam1-rac1 is a critical component in the biology of human tumors, in both transformed cells as well as the cells in the tumor micro-environment (9) (10) (11) . Tiam1 is a potent modifier of oncogenic Ras-induced skin tumor initiation, promotion, and progression. Furthermore, Tiam1 expression was found to be up-regulated in a subset of carcinomas (12) (13) (14) . In some other cancers, however, Tiam1 was found to suppress tumor invasion and metastasis (15, 16) . Since Tiam1 plays different roles depending on the cancer type, we investigated the role of Tiam1 in pancreatic cancer proliferation and invasion.
The mechanism underlying the cross-talk between Tiam1-rac1 and the canonical Wnt signaling pathway has been studied in colorectal cancer cells (17) . Rac1 binds to the ȕ-catenin/TCF transcription factor complex at Wnt-responsive promoters to enhance Wnt target gene transcription (18, 19) . The canonical Wnt signaling pathway coordinates various cellular processes such as cell proliferation and cell fate determination during embryonic development and adult tissue maintenance (20) . Furthermore, Wnt signaling has been shown to result in the stabilization and nuclear accumulation of ȕ-catenin, the key mediator of the pathway. In the nucleus, ȕ-catenin binds to members of the T-cell factor/lymphoid-enhancer factor (TCF/LEF) family of HMG-box transcription factors to activate the transcription of target genes, including CDK4 and cyclin-D1 (21) . In most situations, rac1 and RhoA exhibit an antagonistic relationship at multiple levels and there is balance between the activities of rac1 and RhoA (22) (23) (24) (25) . This opposition can be reciprocal and unidirectional, as observed in NIH3T3 cells, in which rac1 activation induces epithelial cell morphology, including cadherin-based junctions, accompanied by decreased RhoA activity. Elevation of RhoA activity reversed the phenotype, promoting a mesenchymal fibroblastic morphology (26) . Quantitative in vivo fluorescence life-time imaging illustrated that RhoA is not only necessary for invasion, but that subcellular spatial regulation of RhoA activity, as opposed to its global activity, is likely to govern invasion efficiency in vivo (27) .
We hypothesized that Tiam1-rac1 and RhoA may be involved in pancreatic cancer proliferation and invasion. We tested this hypothesis and determined whether these factors may be potential therapeutic targets in patients with pancreatic cancer.
Materials and methods

Cell lines and human tissues
Human pancreatic carcinoma cell lines (BxPC-3 and panc-1) were purchased from the Cell Repository, Chinese Academy of Sciences (Shanghai, China). BxPC-3 was grown in RPMI-1640 (Hyclone, USA) and panc-1 was grown in DMEM (Hyclone), supplemented with 10% FBS (Gibco, USA), 100U/ml penicillin G and 100 μg/ml streptomycin (Sigma-Aldrich, USA), at 37°C in a humidified 5% CO 2 incubator. 
Immunohistochemistry
Three micrometer thick paraffin embedded sections were incubated overnight at 4°C with primary antibodies against Tiam1 (Santa Cruz, USA; 1:100), cyclin-D1 (Boster, China; 1:100), and ki67 (Boster; 1:100), and then were washed and incubated for 30 min with biotinylated goat anti-rabbit IgG. The sections were washed thoroughly, stained with diaminobenzidine and examined by an Olympus BX41 microscope (Olympus, Japan). Six randomly selected fields of each section were examined by two pathology specialists blinded to patient diagnosis and outcome. Image-Pro Plus Version 6.0 (Media Cybernetics, USA) software was used for analysis, and areas positive for Tiam1 expression and average optical density (AOD) were recorded.
Immunofluorescence
BxPC-3 cells grown on cover slips were incubated overnight at 4°C with primary antibody to E-cadherin (CST, USA, 1:100), followed by incubation for 45 min at 37°C with CY3-conjugated goat anti-rabbit antibody (Boster). F-actin distribution was detected using rhodamine phalloidin (Sigma-Aldrich) according to the manufacturer's protocol. Slides were counterstained with DAPI to visualize the cell nuclei and photographed using a LEICA LCSSP2 confocal laser scanning microscope (× 400) and analyzed by ZEN 2009 (Carl Zeiss, Germany). shRNA Silencing of Tiam1
The shRNA sequence targeting Tiam1 was cloned into the plasmid pLVX-GFP (Neuron Bio, China). As a control, scrambled shRNA with no target was cloned into pLVX-GFP.
Lentiviruses were produced and titrated by standard protocols. Each preparation contained
1×10
8 TU/ml with an approximate 1:100 ratio of TU to physical particles, as quantitated by PCR. BxPC-3 and panc-1 cells were seeded in cell vessels the day before transduction, ensuring that the cells would grow to 30-40% confluence the next day, and infected for 24 h with lentivirus at an MOI of 50 in the presence of polybrene (5 mg/ml, Sigma-Aldrich).
Stably transduced cells were obtained by sorting for GFP.
siRNA for rac1 and ȕ-catenin
The specific nucleotide RNAs and Scramble siRNA were chemically synthesized by Ribobio 
RNA Preparation and Real-Time PCR
Total RNA was extracted from human primary pancreatic cancer cells using a TRIzol kit (Invitrogen) according to the manufacturer's instructions. A 2 μg aliquot of each total RNA was reverse transcribed to cDNA using a ReverTra Ace qPCR RT Kit (Toyobo, Japan).
Quantitative real-time PCR was performed using a SYBR Green Realtime PCR Master Mix Cell invasion and migration were analyzed using 24-well Corning Costar inserts of pore size 8 μm. For invasion assays, the upper surface of each insert was coated with diluted matrigel (BD, USA) for 6 h in an incubator. Cells (100,000) were added to the upper chamber and incubated at 37°C, with migration assessed at 12 h and invasion at 24 h. Non-migrating or non-invading cells were removed with a cotton swab from the top chamber. Cells remaining in the bottom chamber were fixed with 100% methanol, stained with 1% crystal violet in 2% ethanol, and quantified visually in nine random fields using bright-field optics. Values for triplicate membranes are reported as the mean ± the standard deviation of the number of cells per millimeter squared.
G-LISA assay
RhoA and rac1 activity were measured using the G-LISA Assay System (Cytoskeleton, USA) according to the manufacturer's protocol.
Growth inhibition assay
Growth inhibition was measured using CCK-8 assays (Dojindo, Japan) and EDU tests (Ribobio). Briefly, cells were seeded in 6-well culture plates at a density of 50,000 cells per well or in 96-well culture plates at a density of 3000 cells/well, grown for 24 h and transfected for 24 h. The medium was removed, fresh medium was added, and the cells were maintained in culture for an additional 48 h. CCK-8 and EDU assays were performed to assess growth inhibition.
In Vivo Treatment of Established Pancreatic Cancers
Single-cell suspensions were either subcutaneously transplanted or orthotopically implanted transplanted pancreatic cancer model, half the mice in each group were sacrificed 6 weeks after initiation of treatment, and the tumors were evaluated macroscopically and microscopically. The remaining mice were kept alive until day 80 to monitor the progression of disease. In the orthotopically implanted pancreatic cancer model, tumor growth was assessed on day 42 by palpation and confirmed by magnetic resonance imaging. The study was continued until day 100 to monitor progression/putative relapse of disease. Mice were assessed with a 7-Tesla MRI system (Bruker Biospec, Germany) using a dedicated small animal coil. This study was carried out in strict accordance with the recommendations in the 
Statistical analyses
Results for continuous variables are presented as means ± standard deviation (SD) unless stated otherwise. Treatment groups were compared with the independent sample t test.
Pair-wise multiple comparisons were performed with the one-way ANOVA (two-sided). A value of p < 0.05 was considered statistically significant. All analyses were performed using SPSS 17.0 (SPSS Inc., USA).
Results
Expression of Tiam1 in pancreatic cancer tissues
We first investigated whether Tiam1 protein was expressed in pancreatic cancers, pancreatic showed that normal pancreas tissue samples were negative for Tiam1, benign tumors were weakly positive, and adenocarcinomas were strongly positive (Fig. 1A) . Most of the Tiam1 was localized in the cytoplasm (Fig. 1A) . We found that Tiam1 expression differed significantly among the three sets of samples, normal pancreas, benign tumors and adenocarcinomas (Fig. 1B) , but there was no significant difference between the different grades of differentiation (Fig. 1C) . Histological examination of the 53 adenocarcinomas showed that 38 had lymph node involvement and/or distant metastasis (group A), whereas the other 15 could be categorized as without lymph node involvement or distant metastasis (group B). The expression of Tiam1 was significantly higher in tumors from patients without lymph node involvement and/or distant metastasis than those with lymph node involvement and/or distant metastasis (Fig. 1D ).
Tiam1-rac1 promotes proliferation and growth of pancreatic cancers via the Wnt signaling pathway
Our finding that Tiam1 expression was stronger in malignant tumors than in benign tumors and normal pancreas suggested that Tiam1 may play an important role in pancreatic cell proliferation and tumor growth. To assess the role of Tiam1 in pancreatic cancer biology, we generated stable BxPC-3 and panc-1 cell lines expressing a short hairpin RNA against Tiam1 using a lentiviral delivery system (Fig. S1A) . Western blot and real-time RT-PCR analyses showed that specific shRNA suppressed the expression of Tiam1 RNA and protein (Fig. S1B,   S1C) . Moreover, the level of activated rac1 was down-regulated in both cell lines (Fig. S1D ).
We also found that cell growth and proliferation were markedly suppressed ( Fig. 2A, 2B ). 
To elucidate the mechanisms involved in the growth inhibition induced by Tiam1 knock-down, we analyzed the expression in these cells of mRNA encoding cyclin-D1 and CDK4, genes that contribute to cell cycle progression. Knock-down of Tiam1 down-regulated the expression of cyclin-D1, but not of CDK4 (Fig. 2C) . Since cyclin-D1 is a target gene of the Wnt signaling pathway, we measured the mRNA expression of its main targets: c-myc, c-jun and cyclin-D1. We found that suppression of Tiam1 markedly down-regulated the expression of c-myc and cyclin-D1 mRNAs, while slightly decreasing the expression of c-jun mRNA (Fig. 2D ). These findings suggested that Tiam1-rac1 promotes pancreatic cancer proliferation and tumor growth via the Wnt signaling pathway.
To explore the mechanism underlying the interaction of Tiam1-rac1 with the canonical Wnt signaling pathway, we performed western blotting assays of the expression of ȕ-catenin in the cytosolic and nuclear fractions of BxPC-3 cells with or without Tiam1 knock-down. We found that Tiam1 knock-down did not affect ȕ-catenin stabilization in the cytosol but markedly reduced ȕ-catenin accumulation in the nucleus (Fig. 2E) . This result was supported by our immunofluorescence experiments (Fig. 2F) , indicating that Tiam1 is required for nuclear localization of ȕ-catenin.
We next investigated the molecular mechanism by which Tiam1 is required for the nuclear localization of ȕ-catenin. Tiam1 is a guanine nucleotide exchange factor that selectively activates the Rho-like GTPase rac1. We assayed ȕ-catenin expression by western blotting in the nucleus of BxPC-3 and panc-1 cells, following transfection with rac1 or ȕ-catenin siRNA or treatment with the rac1 specific inhibitor NSC23766. We found that disruption of rac1 activity reduced ȕ-catenin expression in the nucleus (Fig. 2G, S1E ). To corroborate our 
previous findings, we examined the role of Tiam1-rac1 in the regulation of cyclin-D1 expression, and found that rac1 knock-down or a rac1 specific inhibitor reduced cyclin-D1 expression by ~50% (Fig. 2H) . Using CCK-8 and EDU assays, we found that disruption of rac1 activity by transfection with si-rac1 or treatment with NSC23766 inhibited cell proliferation, similar to that observed with Tiam1 knock-down. Taken together, our findings demonstrated that Tiam1-rac1 amplifies the Wnt signaling pathway activity by promoting ȕ-catenin accumulation in the nucleus, and augments Wnt target gene transcription.
Tiam1-rac1 promotes pancreatic cancer growth in vivo
To determine if Tiam1-rac1 inhibition affects tumor growth in vivo, we tested the effects of Tiam1 knock-down and the rac1 inhibitor NSC23766 on human pancreatic cancers established in BALB/c nude mice. The details of the experimental setup are depicted in Figure 3A . We found that both Tiam1 knock-down and NSC23766 significantly inhibited tumor growth (Fig 3B-3C ). Histological evaluation of the tumors confirmed that Tiam1 knockdown markedly reduced Tiam1 expression, and somewhat reduced cyclin-D1 and ki67 expression, with the latter also observed in cells treated with NSC23766 (Fig 3E) . During long-term follow-up, however, blocking Tiam1-rac1 did not prolong overall survival time (Fig 3D) .
Balance between rac1 and RhoA activities in pancreatic cancer cells
Because the expression of Tiam1 was significantly higher in the primary tumors of patients without lymph node involvement than with involvement and/or distant metastasis, we hypothesized that blocking Tiam1 may activate other signaling pathways, and that these latter rac1 and RhoA activities has been shown to regulate cell migration and invasion in many cancers, with down-regulation of rac1 leading to activation of RhoA. We therefore hypothesized that Tiam1 knock-down would down-regulate rac1, leading to the activation of RhoA, which promotes the invasion and metastasis of pancreatic cancer cells. Using G-LISA assays to measure Rac1 and RhoA activity after Tiam1 knock-down, we found that rac1 activity was down-regulated, whereas RhoA activity was up-regulated ( Fig 4A) . We therefore examined rac1 and RhoA activity following treatment of BxPC-3 cells with NSC23766, C3 transferase, which non-selectively inactivates the GTPases RhoA, RhoB, and RhoC in vivo and in vitro, or Y27632, which is a selective inhibitor of Rho-associated protein kinases that has no effect on RhoA activity, but can inhibit the effects of RhoA in vitro and in vivo. We found that NSC23766 down-regulated rac1 and up-regulated RhoA activity, whereas C3 transferase down-regulated RhoA and up-regulated rac1 activity (Fig 4A) . The combined use of NSC23766 and C3 transferase could down-regulate both rac1 and RhoA activity (Fig 4A) .
Y27632 did not impact RhoA activity, but slightly up-regulated rac1 activity (Fig 4A) . These findings indicate that inhibiting Tiam1-rac1 with Tiam1 knock-down or NSC23766 activates RhoA, whereas inhibiting RhoA activity with C3 transferase activates rac1. Although Y27632 had no impact on RhoA activity, it can block its biological effects and lead to the up-regulation of rac1 activity. Thus, taken together, these findings demonstrate a balance between rac1 and RhoA activities in pancreatic cancer cells. As C3 transferase non-selectively inactivates the GTPases RhoA, RhoB, and RhoC, whereas Y27632 can selectively inhibit Rho-associated protein kinases and thus block RhoA biological effects, we choose Y27632 for the next experiment. 
Combined inhibition of rac1 and RhoA down-regulates pancreatic cancer cell invasion and migration
We next investigated the role of Tiam1 in the invasive capacity of pancreatic cancer cells. In a wound healing assay, we found that Tiam1 knockdown accelerated the wound closure rate at 24 h compared with controls (Fig 4B, S2A) . In a transwell migration and invasion assay, knockdown of Tiam1 resulted in a 2-fold increase in the number of cells that passed through the membrane compared with the controls (Fig 4C, 4D, S2B, S2C ). As expected, knock-down of Tiam1 was accompanied by enhanced invasiveness of BxPC-3 and panc-1 cells. In the absence of knock-down, BxPC-3 cells had an epithelial-like morphology, with E-cadherin and F-actin arranged in a cortical pattern at cell-cell junctions. After Tiam1 knock-down, E-cadherin was no longer observed at cell-cell junctions, and F-actin stress fibers were present (Fig 4E) .
We next investigated the effects of rac1 and RhoA on the invasive capacity of pancreatic cancer cells. We found that treatment with the rac1 specific inhibitor NSC23766 markedly increased the percentage of migrated cells, whereas treatment with Y27632 had no effect Based on these promising findings, we assessed whether inhibition of rac1 and RhoA could increase progression-free survival in BALB/c nude mice with pre-established pancreatic cancers. Xenografts were established by orthotopic implantation of BxPC-3 cells into BALB/c nude mice and treatment was started 1 week after injection (Fig. 5A) . Because only the combination of NSC23766 and Y27632 decreased cell growth and invasion in vitro, we focused on this treatment regimen. Tumor growth was assessed on day 42 by palpation and confirmed by magnetic resonance imaging (MRI) (Fig 5B) . No tumors were detected in mice receiving combination therapy, so the study was continued until day 100 to monitor progression-free of disease. Over time, control animals bore large, life-limiting tumors and succumbed within 60 days of tumor implantation. All animals treated with NSC23766 alone showed progressive disease and succumbed within 60 days. Mice treated with NSC23766 and Y27632 showed significantly better long-term survival than those treated with NSC23766 alone, with 80% of the former group surviving to day 100 (Fig 5C) , and histological evaluation of the liver showing the absence of metastatic sites (Fig 5D) .
Discussion
Patients with pancreatic cancer have a devastating prognosis, in part due to the lack of 
effective chemotherapeutic agents (28) . Tiam1 and its downstream target gene rac1 are frequently deregulated in human cancers. Tiam1-rac1 can antagonize RhoA activity directly at the GTPase level, and vice versa (24, 29) . We provide in vitro and in vivo evidence that the balance of Tiam1-rac1 and RhoA drives the proliferation and invasion of pancreatic cancer cells and provides a target for combined therapy.
We found that the expression of Tiam1 protein was significantly higher in pancreatic cancers than in corresponding normal pancreas cells and pancreatic benign tumors. Tiam1, a rac1-specific GEF, has been associated with a variety of tumor types (30, 31) , suggesting that Tiam1 may be important in the proliferation and growth of these cancers and act as a tumor promoter. We also found that the presence of lymph nodes or distant metastases was significantly associated with reduced expression of Tiam1. In fact, loss of Tiam1 expression has been associated with increased malignancy and invasiveness in skin tumor models, and Tiam1 protein expression was shown to be weaker during breast cancer (32) and gastric cancer progression (33) , suggesting that Tiam1 may act as a suppressor of invasion and migration. Our immunohistochemical results suggested that Tiam1 may play opposite roles in pancreatic cancer cell proliferation and invasion. Thus, inhibiting Tiam1 activity in pancreatic cancer may not be beneficial.
We found that Tiam1 silencing in BxPC-3 and panc-1 cell lines significantly arrested cell proliferation. The specificity of Tiam1-rac1 is determined by the effect of rac1 on specific downstream pathways. We proved that activation of rac1 promoted ȕ-catenin accumulation in the nucleus and synergized with ȕ-catenin to augment Wnt signaling associated target genes transcription. Tiam1 was recently shown to be a Wnt-responsive gene and promote the 
formation and progression of intestinal tumors and breast cancers (19, 34, 35) . Rac1 is a component of transcriptionally activating ȕ-catenin/TCF complexes at Wnt-responsive promoters, and in the presence of Tiam1, the rac1 complex enhances target gene transcription (19) . Moreover, ȕ-catenin is a key mediator of the canonical Wnt pathway, as it is associated with members of the T-cell factor (TCF) family at Wnt-responsive promoters to drive the transcription of Wnt target genes (21) . We found that Tiam1-rac1 amplified the Wnt signaling pathway activity by promoting ȕ-catenin accumulation in the nucleus, and that it augmented Wnt signaling pathway targeted gene transcription in pancreatic cancer cells. # In a pancreatic cancer subcutaneously transplanted model, we found that blocking Tiam1-rac1 slowed tumor growth, but did not prolong overall survival time. Because Tiam1 expression was stronger in pancreatic tumors of patients without lymph node involvement and/or distant metastases than those with lymph node involvement and/or distant metastases, we hypothesized that blocking Tiam1-rac1 may activate other signaling pathways, which may promote the invasion and metastasis of pancreatic cancer cells.
The balance of rac1 and RhoA activities has been found to regulate cell proliferation and the invasion of many cancers (36) . Down-regulation of rac1 activity can activate RhoA through p120-catenin and p190RhoGAP (24) or through other signaling pathways. In contrast, down-regulation of RhoA could activate rac1 through complicated mechanisms (22) . Thus, blocking Tiam1-rac1 by Tiam1 knockdown or use of the rac1 specific inhibitor NSC23766 leads to the up-regulation of RhoA activity. RhoA promotes the invasion and migration of pancreatic cancer cells (27, 37, 38) . We observed a balance between rac1 and RhoA activities in pancreatic cancer, finding that blocking Tiam1-rac1, either by Tiam1 knock-down or the 
